in blood is a marker of ovarian status in women and the presence of cryptic testes in babies. Despite this, the molecular form of AMH in blood has not been verified. AMH is synthesized as an inert proprotein precursor (proAMH), which can be cleaved to yield NH2-terminal (AMHN) and COOH-terminal (AMHC) fragments, that can complex noncovalently (AMHN,C). Developing males have 10-fold more AMH than young adults. We report here that human blood is a mixture of inactive proAMH and receptor-binding AMH N,C. The AMH in the blood of boys, men, and premenopausal women was immunoprecipitated using antibodies to the NH2-and COOH-terminal peptides. The precipitated proteins were then analyzed by Western blots, using recombinant proteins as markers. The glycosylation status of AMH was verified using deglycosylating enzymes. The NH 2-terminal antibody precipitated a major protein that migrated alongside rhproAMH and was detected by anti-AMHN and anti-AMHC. This antibody also precipitated significant levels of AMHN and AMHC from all participants. Antibodies specific to AMHC precipitated rhAMHC but did not precipitate AMHC from human blood. Hence, all the AMHC in human blood appears to be bound to AMHN. Both AMHN and proAMH were glycosylated, independent of age and sex. In conclusion, boys and young adults have the same form of AMH, with a significant proportion being the inactive precursor. This raises the possibility that the endocrine functions of AMH are partly controlled by its cleavage in the target organ. The presence of proAMH in blood may confound the use of AMH for diagnosis. sex; boys; anti-Müllerian hormone enzyme-linked immunosorbent assay; pro-anti-Müllerian hormone; amino-and carboxy-terminal antiMüllerian hormone; menopause; ovarian reserve; furin THE HORMONAL CONCENTRATION of anti-Müllerian hormone (AMH, also known as Müllerian-inhibiting substance) varies with sex and age. AMH is initially male specific, with male embryos and prepubescent boys having high levels of AMH in their blood (2, 16). AMH triggers the degeneration of the uterine precursor in early male embryos, after which it contributes to the male biases in the lung (7), brain (19, 21, 32, 34) , and possibly other tissues.
AMH reporters in some cell lines (3, 12, 33) , with the maintenance of blood vessels and insulin homeostasis being putative adult functions for AMH (10, 30) . In women, the levels of AMH decline as ovarian reserve diminishes, enabling it to be used extensively as a biomarker of ovarian status (30) .
The abovementioned studies of AMH in women and boys tacitly assume that there is a single molecular form of AMH in blood, which does not vary with age or gonadal pathology. A priori, this is not necessarily the case. AMH is synthesized as a glycosylated (3, 13, 23, 24) cysteine-linked homodimer of the 560-amino acid preproprotein (6) . The first 24 amino acids are removed during synthesis, yielding the propeptide (proAMH) (6) , which does not activate AMH receptors (10, 14) . Enzymatic cleavage at a monobasic recognition site between amino acids 451 and 452 (where amino acid 1 is the start-coding methionine) yields a 25-kDa COOH-terminal dimer (AMH C ) and 120-kDa NH 2 -terminal dimer (AMH N ), which initially remain associated in a noncovalent complex (AMH N,C ) (22) . AMH C is the receptor-activating component (9, 14) . Some recombinant forms of AMH also contain alternatively cleaved AMH, which yields an extended COOH-terminal peptide consisting of amino acids 255-560 (AMH ) (25) .
The AMH in blood is generally presumed to be the bioactive cleaved form based on a historic investigation of a sex-cord tumor patient with pathologically elevated levels of AMH (25) . However, proAMH is present in ovarian follicular fluid (5) and is released from rat and bovine testes in organ cultures (20, 23) . This raises the possibility that blood contains a mixture of AMH species, with different receptor-binding characteristics. We report here that the blood of boys, men, and premenopausal women contains significant levels of both proAMH and AMH N,C .
METHODS
Study participants. Study participants were healthy individuals recruited from the community in Dunedin, New Zealand, in the categories of boys, men, and women of reproductive age. A single postmenopausal woman was recruited as a negative control; postmenopausal women lack serum AMH (8) . Blood samples from plasma were collected in EDTA-coated tubes (BD), and the plasma was obtained by centrifugation at 2,000 g for 5 min. Serum from prepubescent boys was collected as previously described (18) . The plasma and serum samples were immediately snap-frozen and stored at Ϫ80°C. The sex, age, and blood AMH concentration of each participant is recorded in Table 1 . This project was approved by the University of Otago Human Ethics Committee, and all participants were volunteers. Informed consent was obtained directly from all adult participants, and parents or legal guardians provided consent on behalf of the children who participated.
Recombinant AMH. Recombinant human AMH (rhAMH) was produced from HEK293 cells transfected with a proAMH vector [Px'Therapeutics (Grenoble, France), under contract to the University of Otago]. The resultant rhAMH was a mixture of proAMH, with lesser amounts of AMH N,C (Fig. 1) . rhAMHC was purchased from R&D Systems (1737-MS).
An aliquot of the rhAMH (Px'Therapeutics) was cleaved with furin to convert a proportion of the proAMH to AMH N,C. Approximately 10 mM rhAMH was reacted with 8 units of furin (New England Biolabs) in 40 l of reaction buffer consisting of 100 mM MES, pH 6.5, 0.3 mM Ca 2ϩ , 12 mM Na ϩ , and 107 mM K ϩ for 24 h at 37°C. The reaction was stopped by the addition of Laemmli buffer and heating to 95°C for 5 min. A second aliquot of rhAMH was subjected to the same treatment except that no furin was added to the reaction buffer.
Enzyme-linked immunosorbent assay. The AMH concentration in the plasma and serum samples and the rhAMH were assayed using the AMH gen II enzyme-linked immunosorbent assay (ELISA) kit (Beckman Coulter). Standard curves for interpolation were generated by fitting a quadratic curve to the absorbance values obtained for the AMH standard solutions (Beckman Coulter).
Immunoprecipitation of AMH with agarose beads. AMH was immunoprecipitated from 1 ml of serum or plasma with 1 g of either an anti-NH 2-terminal antibody (catalog no. AF2748, raised to amino acids 19 -450 of human AMH; R&D Systems) or antibodies to the COOH-terminal peptide (catalog no. AF1737, raised to amino acids 453-560 of human AMH or catalog no. AF1446, raised to amino acids 447-553 of rat AMH; R&D Systems) (see Figs. 1-6 ). Incubation was conducted overnight at 37°C with 0.03% sodium azide (Merck), 1 mM phenylmenthanesulfonyl fluoride (Sigma), and complete mini protease inhibitor cocktail (Roche) diluted as per the manufacturer's instruction. Fifty microliters of rabbit anti-goat IgG Trueblot beads were then added to the solution, which was incubated for 1 h at room temperature before the centrifugation at 6,700 g for 30 s. The supernatant was removed, and the beads were washed three times in 0.01 M phosphate buffer (PB) and then heated to 95°C in Laemmli buffer for 5 min. The released proteins were run on SDS-PAGE (10% bisacrylamide with 4% stacking gel) for Western blotting.
Enzymatic deglycosylation of AMH from human blood. The primary antibody was cross-linked to the beads for the analysis of the gycosylation state of AMH to minimize the breadth of the IgG band (see Fig. 6 ). Rabbit anti-goat IgG Trueblot beads were incubated with goat anti-human AMH propeptide antibody for 1 h at room temperature with agitation. The beads were rinsed two times with 0.01 M PB and two times with 0.2 M triethanolamine (BDH), pH 8.2. The associated proteins were cross-linked with 25 mM dimethyl pimelidate dihydrochloride (Sigma), 0.2 M triethanolamine, pH 8.2 for 45 min at room temperature. The reaction was stopped with one quick rinse, followed by 1 h of incubation in 0.1 M ethanolamine (Sigma), pH 8.2. The beads were rinsed two times with 0.01 M PB, and unbound antibody was eluted with 0.1 M glycine hydrochloride (BDH), pH 2.5 followed by two rinses in 0.01 M PB.
The plasma of boy B3 and the serum of boy B4 were diluted 1:2 with 0.01 M PB. The AMH was immunoprecipitated from the sample with 1 g of goat anti-human AMH propeptide antibody cross-linked to rabbit anti-goat IgG Trueblot beads. Incubation was conducted overnight at 37°C with 0.03% sodium azide (Merck), 1 M phenylmenthanesulfonyl fluoride (Sigma), and complete mini protease inhibitor cocktail (Roche) diluted as per the manufacturer's instruction. The beads were then rinsed two times with 1 ml 0.01 M PB, resuspended in 1 ml 0.01 M PB, and transferred to a new microtube. Enzymatic deglycosylation was conducted using the EDEGLY enzymatic deglycosylation kit (Sigma). To elute the precipitated AMH, the beads were pelleted, the supernatant was removed, and 60 l of ultrapure water, 25 l of the 5ϫ reaction buffer, and 2.2 l of 5% SDS (Sigma) solution were added. The sample was heated to 95°C for 5 min, and the supernatant was transferred to new tubes in 21-l aliquots. Disulfide bonds in the samples were reduced with 0.9 l of 2-mercaptoethanol and heating to 95°C for 5 min. To each sample, 1.2 l of 15% Triton X-100 and 0.5 l of each required deglycosylation enzyme [␤-N-acetylglcuosaminidase, Sialidase A, O-glycosidase, ␤(1¡4)-galactosidase, and/or PNGase F] were added followed by incubation at 37°C for varying lengths. Samples were analyzed by Western blot.
Western blotting. SDS-PAGE was run on 10% Tris-glycine bisacrylamide gels with 4% stacking gel at 100 volts for 1.5 h using the Xcell Surelock Mini-Cell system (Invitrogen). Proteins were transferred to a 0.4-m nitrocellulose membrane (Whatman) at 30 volts for 1 h on ice. Blotting membranes were blocked with Odyssey blocking The levels of AMH were measured using the Beckman Coulter Gen II ELISA. AMH, anti-Müllerian hormone. reagent (Licor) for 30 min. Primary antibodies (catalog nos. AF2748 and AF1446; R&D Systems) were diluted to 0.1 g/ml and incubated overnight at 4°C in blocking reagent. Rinsing and addition of fluorescent secondary antibodies were conducted using the SNAPi.d. vacuum filtration system (Millipore). After rinsing, IRDye680 Donkey anti-goat IgG antibody (Licor) was applied at 1 g/ml for 10 min before final rinsing and drying of the blotting membrane. The blotting membrane was imaged using the Odyssey fluorescent infrared scanner (Licor). The voltage (gain) to the photomultiplier tube was used to vary the intensity of the blot depending on the signal strength of the relevant bands. The grayscale has been inverted to present the image as black-on-white images.
Image quantification. The density of the faint bands in one of the Western blots was quantified without image manipulation, using Image J software (NIH, http://rsbweb.nih.gov/ij/) (see Fig. 5A ). The image was then enhanced for visualization (see Fig. 5B ). This involved a linear stretch of the dynamic range of the image intensity such that the range of pixel intensities occupied by the histogram was linearly recalculated to occupy the full 256-bit space with image J. The "dust and speckles" filter in Photoshop CS5 (Adobe) with a pixel radius of 6 and a threshold of 10 (image resolution: 300 pixels/in.) was used to reduce the autofluorescent dust particles in the image.
RESULTS

Validation of AMH antibodies for Western blotting.
The molecular weights and immunoreactivity of proAMH, AMH N , AMH C , and AMH 255-560 in a reducing-conditions Western blot were examined using antibodies to the NH 2 -and COOHterminal portions of AMH (Fig. 1, A and B, respectively) . The rhAMH derived from HEK cells was predominantly a 72-kDa species, with lesser amounts of other forms of AMH. The 72-kDa species is designated proAMH and was detected by both the COOH-and NH 2 -terminal antibodies, with the NH 2 -terminal antibody having a higher affinity than the COOHterminal antibody. The identity of the band was further confirmed as its intensity was diminished by pretreatment with the proprotein convertase furin (Fig. 1, A and B) . AMH C at 12.5 kDa was detected exclusively by the COOH-terminal antibody (Fig. 1B) , whereas two AMH N bands at 62 and 64 kDa were detected exclusively by the NH 2 -terminal antibody (Fig. 1A) . The intensity of the AMH C and AMH N bands increased following furin treatment, providing further confirmation of their identities. A lower-abundance 47-kDa band was also present. This band contained both NH 2 -and COOH-terminal epitopes, with its size being consistent with the previously described AMH .
The level of AMH in blood is too low to be directly analyzed by Western blots, necessitating prior concentration by immunoprecipitation, which introduces IgG and other bands with affinity to the secondary antibody. This was examined by immunoprecipitation of control goat IgG spiked into a serum sample from man M4, followed by detection with secondary antibody only (Fig. 1C) . The location of the IgG bands (Fig.  1C, lane 4) was distinct from the bands detected in the blots of the various rhAMH species (Fig. 1, A and B) . The faint IgG bands at ϳ47 kDa (Fig. 1C, lane 4) would not obscure the presence of substantial levels of AMH (Fig. 1, A and B) . No bands were observed when the immunoprecipitation beads alone were added to adult male serum (M4, Fig. 1C, lane 3) .
AMH N,C and proAMH are present in human blood. The blood of a 4-yr-old boy (B1) was then examined by separate immunoprecipitation with anti-NH 2 -or anti-COOH-terminal antibodies, followed by separate detection with the anti-NH 2 -and anti-COOH-terminal antibodies. The strongest band immunoprecipitated by the NH 2 -terminal antibody had the characteristics of proAMH, that is, a 72-kDa protein that reacts with both the anti-COOH-and anti-NH 2 -terminal antibodies (Fig. 2, A and B) . This band was not detected in the blot of a postmenopausal woman (Fig. 2, A and B) , who only had trace levels of AMH (Table 1) . These results suggest that significant levels of proAMH are present in human blood.
The NH 2 -terminal antibody also immunoprecipitated bands with molecular weights appropriate for AMH N ( Fig. 2A ) and AMH C (Fig. 2B) . Neither of these bands was present in the negative control (postmenopausal woman). The detection of AMH C suggests it is coimmunoprecipitating as part of the AMH N,C complex, since the antibody to the NH 2 -terminal domain does not directly bind to AMH C (Fig. 2A) .
The COOH-terminal antibody immunoprecipitates rhAMH C (Fig. 3, lane 2) but does not precipitate protein from the rhAMH (Fig. 3, lane 3) , which is a mix of proAMH and AMH N,C (Fig. 1) . This suggests that the binding epitopes for the COOH-terminal antibody are masked by the NH 2 -terminal domain of AMH in proAMH and AMH N,C . The COOHterminal antibody precipitated trace levels of AMH N from the blood of boy B1, with no detectable levels of either AMH C or proAMH. Hence the boy's blood appeared to contain little or no free AMH C , providing independent validation that the AMH C precipitated by the anti-NH 2 antibody is the result of the presence of AMH N,C in blood. The trace AMH N band suggests that the anti-COOH-terminal antibody inefficiently precipitates AMH N,C , with the greater sensitivity of the NH 2 -than the COOH-terminal detection permitting the visualization of the precipitated AMH N .
In subsequent experiments, the anti-NH 2 -terminal antibody was used for immunoprecipitation, with a combination of the anti-NH 2 -and anti-COOH-terminal antibodies used for the Western blots to ensure that all precipitated species were detected.
ProAMH and AMH N,C are present in adult serum, from both sexes. We then examined whether the presence of proAMH and AMH N,C was sexually dimorphic or dependent on the stage of the life cycle. AMH was immunoprecipitated from plasma samples from two additional prepubescent boys (B2, B3), three young men (M1, M2, M3), and three premenopausal women (W1, W2, W3), with a postmenopausal woman included as a control (Fig. 4) . ProAMH and AMH N were detected in the blood of the boys, men, and women (Fig. 4) , with the intensity of the bands being broadly in line with the ELISA estimate of AMH levels (Fig. 4, Table 1 ). The postmenopausal woman had no detectable levels of AMH N and only trace levels of proAMH. The anti-NH 2 -terminal antibody coimmunoprecipitated AMH C from the serum of boys. The density of the AMH C bands in the adult samples was low as expected (Figs. 4 and  5A) . The presence of AMH C was therefore confirmed by densitometry (Fig. 5C) , after which the visibility of the bands was made clearer by linear contrast enhancement (Fig. 5B) . This indicates that AMH N,C is present in adult blood, as well as the more easily detected proAMH.
Glycosylation of circulating AMH. Two AMH N bands were observed in the rhAMH preparation (Fig. 1) , implying variable posttranslational modification. AMH has two putative N-linked glycosylation sites in the NH 2 -terminal region (6) , which may account for this. We therefore examined the glycosylation status of AMH in human blood by observing changes in apparent molecular weight of immunoprecipitated AMH after enzymatic deglycosylation. PNGase F, which removes N-linked glycans at their linkage to asparagine residues (27), (Fig. 1) . The high-molecular-weight bands are evident in low-gain scans (A), with higher gain scan required to detect AMHC (B) (see also Fig. 5 ). The first lane is the molecular weight marker. Fig. 5 . AMHC is coimmunoprecipitated with AMHN from the blood of men and women. The coimmunoprecipitated AMHC in adults was near the detection limit, and the samples from Fig. 4 were therefore run under conditions optimized to detect AMHC (see METHODS). The original scan is illustrated in A and was quantified by densitometry (C). The original image was subsequently enhanced linearly, as described in METHODS (B), to give visual confirmation of the densitometry measurements.
reduced the size of the proAMH and AMH N bands, yielding several lower-molecular-weight species (Fig. 6 ). This heterogeneity was not eliminated when the length of the incubation was increased from 3 to 24 h, indicating the presence of both PNGase F-sensitive and PNGase F-insensitive glycans. A combination of enzymes was therefore used to remove both N-and O-linked glycans. This produced a single AMH N band, with a molecular weight that was slightly smaller than the band produced when only PNGase F was used (Fig. 6B) . Two proAMH bands were present when multiple enzymes were used, with the intensity of the bands being greater than the untreated proAMH (Fig. 6B) , suggesting that glycosylation reduces the affinity of the NH 2 -terminal antibody to proAMH.
The proAMH and AMH N bands in the blood of prepubescent boys and adults run the same respective distance on SDS-PAGE (Fig. 4) , suggesting that AMH is also glycosylated in adults. The lower abundance of AMH in adults makes this difficult to analyze in detail because of the altered immunoprecipitation method required for deglycosylation. The sample from man M5 was the only adult participant with sufficiently high AMH levels to observe proAMH and AMH N bands before and after glycosylation (Fig. 7A) . The densitometry histogram revealed that deglycosylation caused apparent shifts in the molecular weights of the proAMH and AMH N bands of sample M5 (Fig. 7B, lanes 4 and 5) . ProAMH and AMH N were not detectable in the untreated samples from women W4 and W5 (Fig. 7B, lanes 6 and 8) . However, consistent with the increased band intensity observed after AMH deglycosylation in boys and men, the presence of a shifted proAMH band became detectable in both deglycosylated samples from women (Fig.  7B, lanes 7 and 9) . This suggests that proAMH and AMHN are similarly glycosylated in men, women, and prepubescent boys.
DISCUSSION
AMH in blood has been tacitly assumed to be a single molecular species. However, multiple AMH species were precipitated from human blood, with one of the strongest bands in the Western analysis being proAMH, the uncleaved AMH precursor. Significant levels of cleaved product, AMH N,C, were also present. Most, if not all, of the AMH C in blood was held within this complex, since AMH C was most efficiently precipitated by an antibody to the NH 2 -terminal of AMH. In contrast, no AMH C was precipitated from blood by a COOH-terminal antibody, which precipitates rhAMH C . No significant levels of the alternatively cleaved form of AMH, AMH 255-560 , were detected. Thus, the only confirmed AMH species in blood are proAMH and AMH N,C .
The relative levels of proAMH and AMH N,C in blood appeared to vary slightly between individuals but with no overt differences between boys, men, and women. Western blot analysis is only semiquantitative, and AMH species-specific assays will be required to verify this and to examine girls who only have trace levels of AMH. The regulation of proAMH cleavage has been rarely studied, although the possibility of steroidal regulation of proAMH cleavage was raised last century (11) . If this postulate is correct, then the relative abundance of proAMH and AMH N,C in blood may vary with the physiological state of the gonads. This would not be detected by current ELISAs, which give approximate measures of total AMH. Similarly, the cleavage of proAMH may also be affected by gonadal pathology, since the AMH species described in the current study of healthy individuals differs markedly from a prior study of a single patient with a sex cord tumor (25) . The AMH in blood of this patient appeared to be completely cleaved at positions 254/255 and 451/452.
Physiological levels of proAMH do not activate the canonical AMH receptors (9, 33) , which begs the question of why proAMH is secreted into blood. Precedence from other hormones point to two possibilities. Plasma testosterone differentially affects androgen-responsive tissues because of site-specific conversion of testosterone to the more potent dihydrotestosterone. It is therefore possible that AMH N,C provides a low basal stimulation of AMH-responsive cells, with site-specific augmentation resulting from the local cleavage of proAMH to AMH N,C . ProAMH is cleaved by members of the subtilisin/kexin-like proprotein convertases (20) , although it is unknown which members of this family are responsive for cleavage of AMH in vivo. These enzymes have membrane-bound and soluble forms and are expressed by multiple cell types, including neurons (4, 29) and aortic cells (4, 26) , which are putative sites for hormonal actions of AMH (18, 19, 31, 32, 34) . Some of these enzymes are induced in response to pathologies such as vascular injury (17, 26, 28) . Hence, some of the AMH in blood may be in an inactive form, as its function may relate to repair and regeneration rather than to day-to-day regulation of healthy tissues.
The proopiomelanocortin system offers an alternative model for exploring the functions of proAMH. This protein gives rise to multiple distinct cytokines (ACTH, ␣-, ␤-, ␥-MSH, ␤-endorphin, CLIP, ␤-, ␥-lipotropin) depending on how the precursor protein is cleaved. Similarly, the proprotein form of Glassbottom boat, a transforming growth factor-␤ (TGF-␤) superfamily member from Drosophila, has multiple cleavage sites that produce multiple peptides with different functions (1) . This raises the possibility that proAMH is a hormone with function unrelated to AMH N,C signaling through the canonical AMH receptors.
All of the proAMH and AMH N bands were glycosylated (Figs. 6 and 7) , which is consistent with previous in vitro studies (3, 13, 23, 24) . The glycosylation of AMH was heterogeneous, since PNGase F treatment produced multiple proAMH and AMH N bands, with further reduction in molecular weight occurring when a combination of enzymes were used to remove both O-and N-linked glycans. However, the magnitude of this variation was small relative to that previously described for inhibin B, which is a closely related TGF-␤ superfamily hormone (15, 16) . The biological significance of this minor variation is unknown, since the effect of glycosylation on the biological activities of proAMH and AMH N,C has not been studied.
The nomenclature used to describe AMH species is variable in the literature, and in product descriptions of AMH-related products. In some instances, it is unclear which form of AMH has been studied. The AMH species defined here as AMH N,C and AMH N have both been described as proAMH, since they are precursor forms of AMH C . AMH N,C and AMH C have both been referred to as mature AMH. The terminology has developed without the knowledge that the cleaved and uncleaved precursors of AMH coexist in blood. With insulin, and other hormones, the use of "pro" specifically relates to the uncleaved hormonal precursor. We therefore suggest that the term proAMH should only be used to refer to the uncleaved precursor of AMH. The term AMH N,C unambiguously refers to a complex, with the identity of AMH N and AMH C also being evident from their name.
In summary, blood contains a mixture of distinct AMH species. A priori, these species may have different physiological functions and/or be markers of different aspects of gonadal function. Consequently, we argue that proAMH and AMH N,C need to be separately analyzed, in preference to the measurement of total blood AMH levels.
